Engage with the experts in the field of head & neck (H&N) cancer by joining this interactive one-day live meeting. Our experts will provide up-to-date insights into the current and emerging strategies in the management of H&N cancer, including targeted therapy, immunotherapy, and the latest advances in multidisciplinary management and molecular biology. Furthermore, you will learn how to optimally integrate new strategies into your patient care.
Date and Location
Saturday, 15 December 2018
08.00 – 17.00
Le Méridien Taipei
38 Songren Road, Xinyi District
Saturday, 15 December 2018
08.00 – 17.00
Saturday, 15 December
|08.00||Registration and welcome coffee|
|08.30||Welcome, introduction, and demographics|
|08.40||Quiz: Test your expertise in H&N cancer|
|08.50||Setting the Stage—Multimodality treatment approach in H&N cancer: Current standards, challenges, and unmet needs|
|09.15||Q & A|
|09.25||Advances in surgical management of squamous-cell carcinoma of the head & neck (SCCHN)|
|09.50||Q & A|
|10.20||Interactive multidisciplinary tumor board: Early stage H&N cancer|
|11.00||Keynote Presentation—Reaching new heights in the management of H&N cancer: Evolving role of immunotherapy|
|11.25||Q & A|
|11.35||Contemporary management of locally advanced SCCHN|
|12.00||Q & A|
|12.10||Induction therapy for locally advanced H&N cancer: Is there still a role?|
|12.35||Q & A|
|13.45||Interactive multidisciplinary tumor board: Locally advanced SCCHN|
|14.45||Optimal treatment of recurrent/metastatic SCCHN: Front-line therapy and beyond|
|15.10||Q & A|
|15.20||Interactive multidisciplinary tumor board: Recurrent/metastatic SCCHN|
|16.20||What can we expect in H&N cancer management in the near future?|
|16.45||Quiz questions revisited|
Pei-Jen Lou, MD, PhDNational Taiwan University Hospital
Frederic Peyrade, MDAntoine Lacassagne Center
Alexander Guminski, MD, PhDNorthern Sydney Cancer Centre
Royal North Shore Hospital
Sydney, New South Wales, Australia
Ye Guo, MDFudan University Shanghai Cancer Center
Jin-Ching Lin, MD, PhDTaichung Veterans General Hospital
Sadamoto Zenda, MD, PhDNational Cancer Center Hospital East
*Additional faculty to be confirmed
This educational activity is specifically designed for medical oncologists, radiation oncologists, head and neck surgeons, and other healthcare professionals in Asia who are involved in the treatment of patients with H&N cancer.
After successful completion of this educational activity, participants should be able to:
- Evaluate the importance of multidisciplinary care in H&N cancer and how to best apply it for optimal outcomes
- Identify the current role of immunotherapy in the management of SCCHN and ongoing research strategies including combinations of conventional therapies and immunotherapies
- Apply multidisciplinary approaches for managing patients with HPV+ and HPV- locally advanced SCCHN, elderly patients, and those unsuitable for platinum-based chemoradiation
- Select optimal treatment sequence for patients with recurrent/metastatic SCCHN
- Utilize current knowledge to manage complex clinical cases and toxicities related to the management of H&N cancer
- Explain current and emerging therapeutic options for advanced SCCHN after progression on immunotherapy
This educational activity is supported by a grant from Merck KGaA, Darmstadt, Germany.
Independent Medical Education (IME)
This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.
This activity is provided by prIME Oncology.
Sunshine Act/EFPIA Statement
prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.
Disclosure of Relevant Financial Relationships
prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.